ROCHE MOLECULAR SYSTEMS, INC. - BRANCHBURG COBAS® LIAT® SARS-COV-2 & INFLUENZA A/B; COVID-19 MULTI-ANALYTE RESPIRATORY PANEL NUCLEIC ACID DEVICES
|
Back to Search Results |
|
Catalog Number 09211101190 |
Device Problems
Incorrect, Inadequate or Imprecise Result or Readings (1535); Output Problem (3005); Non Reproducible Results (4029)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 11/12/2021 |
Event Type
malfunction
|
Manufacturer Narrative
|
Investigation is ongoing.A follow-up report will be filed upon the completion of the investigation.(b)(4).
|
|
Event Description
|
In light of the covid-19 pandemic and the subsequent emergency use authorizations (euas) for sars-cov-2 diagnostic tests, the agency has requested heightened reporting beyond the reasonably suggests requirements of 803 to include allegations of false positive or false negative results independent of harm or malfunction or off-label use.Pursuant to the agency¿s instruction, we hereby submit this mdr.The customer alleged discrepant results generated for the cobas® sars-cov-2 & influenza a/b (scfa) assay.A customer from the united states alleged that they received a potential false positive result for a patient¿s sample tested with the cobas® sars-cov-2 & influenza a/b (scfa) assay.The customer reported that on (b)(6) 2021 they observed a sars-cov-2 negative, influenza a negative, influenza b positive result for a patient¿s sample tested and analyzed on the cobas® liat® system (s/n14341).The patient¿s same sample was repeat tested on a different platform the cepheid that generated a sars-cov-2 negative, influenza a negative, influenza b negative result.Patient sample was collected using nasopharyngeal swab in remel universal transport media.The customer confirmed there was no allegation of harm to the patient.The negative result was reported out to the patient and/or personnel treating the patient.The investigation to assess the customer allegation has not yet been completed.
|
|
Manufacturer Narrative
|
Instrument data was not provided from the liat for review of instrument performance and it cannot be determined if these samples may have been near the limit of detection (lod) for the influenza b on the scfa assay.The influenza b lod differs significantly between the cobas® sars-cov-2 & influenza a/b test on the cobas® liat system and the cepheid which could explain the sample discrepancies.The lod for cepheid is claimed at 0.19 (victoria) - 0.4 (yamagata) tcid/50ml (depending on the strain).The scfa package insert indicates that the cobas® liat system influenza b lod is 0.002 (brisbabe and florida) - 0.004 (malaysia) tcid/50ml (depending on the strain), which indicates a much more sensitive test versus the cepheid.In addition, the influenza b strains detected can vary from one platform to another.As such, results with one assay may not be reproducible with a different assay.The customer states they believe the issue was due to an expired lot in use that is now discarded.They request the investigation be closed.Although requested, no further information was provided on the lot in use at the time of the allegation.Customer claims they used an expired assay kit.Differences in testing platforms could also contribute to the discrepancy.(b)(4).
|
|
Search Alerts/Recalls
|
|
|